HPV vaccine recommendations. Pediatrics 2012 Mar;129(3):602-5
Date
03/01/2012Pubmed ID
22371460DOI
10.1542/peds.2011-3865Scopus ID
2-s2.0-84857951007 (requires institutional sign-in at Scopus site) 92 CitationsAbstract
On October 25, 2011, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommended that the quadrivalent human papillomavirus vaccine (Gardasil; Merck & Co, Inc, Whitehouse Station, NJ) be used routinely in males. The American Academy of Pediatrics has reviewed updated data provided by the Advisory Committee on Immunization Practices on vaccine efficacy, safety, and cost-effectiveness as well as programmatic considerations and supports this recommendation. This revised statement updates recommendations for human papillomavirus immunization of both males and females.
Author List
Committee on Infectious DiseasesAuthor
Rodney E. Willoughby MD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAdvisory Committees
Age Factors
Female
Forecasting
Health Policy
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Humans
Immunization Programs
Immunization Schedule
Male
Papillomavirus Infections
Papillomavirus Vaccines
Patient Compliance
Practice Guidelines as Topic
Risk Assessment
Sex Factors
United States
